Trials / Recruiting
RecruitingNCT06727812
Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors
A Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-6208 Monotherapy in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 206 (estimated)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open, multicenter Phase I study to evaluate the safety and tolerability of HRS-6208 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-6208 | HRS-6208. |
Timeline
- Start date
- 2024-12-17
- Primary completion
- 2027-08-01
- Completion
- 2027-08-01
- First posted
- 2024-12-11
- Last updated
- 2025-12-18
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06727812. Inclusion in this directory is not an endorsement.